Basic and clinical aspects of platelet integrin αIIbβ3 receptor antagonists in acute coronary syndromes

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 244-249

  Goudevenos, J A ^a   Tselepis, A D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Acute coronary syndromes; Glycoprotein IIb IIIa antagonists; Integrin IIb 3; Percutaneous coronary intervention; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; BETA3 INTEGRIN; C7E3 FAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTEGRIN; INTEGRIN RECEPTOR; LAMIFIBAN; MONOCLONAL ANTIBODY; ORBOFIBAN; SIBRAFIBAN; TIROFIBAN; XEMILOFIBAN;

ANGINA PECTORIS; BLEEDING DISORDER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; HEART INFARCTION; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; BLOOD PLATELETS; CORONARY DISEASE; HUMANS; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0035110774     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs
4. A randomized comparison of antiplatelet and anticoagulant therapy after the replacement of coronary artery stenting
5. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events
6. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy
7. The platelet membrane glycoprotein IIb-IIIa complex
8. Structural biology of glycoprotein IIb-IIIa
9. Signaling through platelet integrin αIIbβ3: Inside-out, outside-in, and sideways
10. The integrin αIIbβ3 in human platelet signal transduction
11. New antiplatelet agents: Platelet GPIIb/IIIa antagonists
12. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa
13. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
15. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
17. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
18. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II
19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
20. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
21. Optimal dosing of a platelet glycoprotein IIb/IIIa antagonist lamifiban using renal-based algorithms in patients with acute coronary syndrome (PARAGON B)
22. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
23. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
24. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
25. GUSTO-IV ACS: Outcome of 7,600 patients with acute coronary syndromes randomized to placebo or abciximab for 1 or 2 days
26. ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction
27. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the TAMI 8 pilot study
28. Combined accelerated tissue-plasminogen activator and platelet IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction
29. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor
30. Abciximab facilitates the rate and extent of thrombolysis: Results of the TIMI 14 trial
31. Trial of abciximab with and without low dose reteplase for acute myocardial infarction
32. Eptifibatide improves both epicardial flow and myocardial reperfusion in patients treated with reduced dose t-PA for acute myocardial infarction. Results of the INTRO-AMI study
33. Randomized, placebo-controlled trial of platelet GP IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA Organization and Randomized trial (RAPPORT) investigators
34. Effect of glycoprotein IIb/IIIa receptor blocked on recovery of coronary blood flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
35. Coronary stenting plus glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction
36. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL study
37. Facilitation of early PCI after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4) pilot trial
38. Long term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
39. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
40. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes
41. A randomised comparison of sibrafiban, an oral glycoprotein IIb/IIIa receptor antagonist with and without aspirin vs aspirin after acute coronary syndromes: Results of the second SYMPHONY trial